Recent News

• 07.30.2026 - Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
• 07.23.2026 - Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
• 07.21.2026 - Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
• 07.02.2026 - New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
• 06.23.2026 - Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
• 06.02.2026 - Myriad Genetics Names Raj Jampa as New Chief Technology Officer
• 05.27.2026 - Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
• 05.26.2026 - Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
• 05.15.2026 - Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
• 05.07.2026 - Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Recent Filings

• 07.30.2026 - 8-K Current report
• 07.30.2026 - EX-99.1 EX-99.1
• 06.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.23.2026 - 8-K Current report
• 06.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.08.2026 - 144 Report of proposed sale of securities
• 06.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.05.2026 - 4 Statement of changes in beneficial ownership of securities